(The Atlantic) – In desperation, the woman’s care team reached out to Müller, a hematologist-oncologist at the University Hospital of Erlangen, a roughly three-hour drive away by ambulance. In recent years, he and his colleagues have made a name for themselves pioneering experimental CAR-T cell treatments—a type of personalized immunotherapy originally developed for cancer—against a variety of autoimmune diseases, with promising early results. Small studies of CAR-T, as well as early results from several ongoing clinical trials, show that many people with autoimmune disease go into remission after treatment; some patients are now years out from CAR-T cell therapy and remain in good health without the help of any drugs. (Read More)